Key facts
- This page summarizes Werner Kroll's Form 4 filing for QUIDEL CORP /DE/.
- 15 reported transactions and 12 derivative rows are listed below.
- Accepted by SEC: 01 Jun 2022, 16:23.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Award
Tax liability
Disposed to Issuer
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Options Exercise
Disposed to Issuer
Disposed to Issuer
Disposed to Issuer
Disposed to Issuer
Disposed to Issuer
Disposed to Issuer
Disposed to Issuer
Disposed to Issuer
Disposed to Issuer
Disposed to Issuer
Disposed to Issuer
Additional SEC filing notes
Section 16 status
Werner Kroll is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Footnote F1
Reflects release of restricted stock units that were previously reported on a Form 4.
Footnote F2
Disposition of shares, as set forth above, was in connection with the Issuer's withholding of common shares to satisfy tax withholding obligations related to the issuance of common shares upon release of restricted stock units.
Footnote F3
Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation ("Quidel"), Ortho Clinical Diagnostics Holdings plc, QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each share of common stock of Quidel beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement will be exchanged for one share of common stock of QuidelOrtho.
Footnote F4
Each restricted stock unit represents the right to receive one share of Quidel common stock.
Footnote F5
Vested in full.
Footnote F6
Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options will be converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions).
Footnote F7
5,888 shares are vested in full; 1,962 shares will vest on February 4, 2023.
Footnote F8
Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions).
Footnote F9
3,925 shares will vest on February 4, 2023.
Footnote F10
Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating employees and will occur according to the elected deferral schedule.
Footnote F11
4,268 shares will vest on February 4, 2023.
Footnote F12
1,962 shares will vest in equal installments on July 1, 2022 and July 1, 2023.
Footnote F13
1,312 shares will vest on February 1, 2023; and 1,313 shares will vest on February 1, 2024.
Footnote F14
3,510 shares will vest in equal installments on July 28, 2022, July 28, 2023 and July 28, 2024.
Footnote F15
3,547 shares will vest on each of January 31, 2023 and January 31, 2024; 3,548 shares will vest on January 31, 2025.
Footnote F16
3,628 shares will vest on January 31, 2024; the remaining 3,628 shares will vest in equal installments on January 31, 2025 and January 31, 2026.